Health Condition 1: C00-D49- Neoplasms
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Sponsors
ACTREC, TMC
Eligibility
Inclusion criteria
Inclusion criteria: 1.Undergoing major oncologic surgery (Gastrointestinal, gynaecology, urology procedures) 2.ASA I-III Elective or emergency surgery 3.Intra-operative vasopressor infusion initiated 4.Planned postoperative ICU/HDU admission
Exclusion criteria
Exclusion criteria: 1.Vasopressor bolus use only (no infusion) 2.Day-care surgeries
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the relationship between intra-operative vasopressor use and postoperative adverse outcomes, including: 1.Acute kidney injury (KDIGO ) 2.Postoperative infection (CDC) 3.30-day mortality 4.Other clinically relevant complications (e.g., need for critical care escalation) (Clavien Dindo greater than and equal to grade III) Timepoint: upto 30 days | — |
Secondary
| Measure | Time frame |
|---|---|
| To describe the current patterns of vasopressor administration during the intra-operative period, including type of agent, total dose, timing, & duration.Timepoint: Intraoperative Period(days of surgery);To identify patient, surgical, & intra-operative factors associated with increased vasopressor requirement, such as type of surgery, baseline comorbidities, blood loss, or intra-operative instabilityTimepoint: From day of surgery to 30 days;To evaluate variation in vasopressor use between surgical specialties & determine whether differences persist after adjusting for patient & procedural characteristics.Timepoint: From day of surgery to 30 days;To describe patterns of fluid therapy (crystalloid & colloid administration) & explore their interaction with vasopressor use & postoperative outcomesTimepoint: From day of surgery to 30 days;. To explore the relationship between intra-operative adverse events (e.g., significant blood loss, arrhythmias, unexpected instability) & subsequent vasopressor dosing patterns.Timepoint: From day of surgery to 30 days | — |
Countries
India
Contacts
Public ContactDr Mohit Hooda
Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
Outcome results
None listed